evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

14 questions · 16 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 6.3%Low 5 · 31.3%Moderate 5 · 31.3%High 5 · 31.3%

Bortezomib vs no bortezomib

Thrombocytopenia · All patients with a diagnosis of multiple myeloma

Bortezomib leads to higher adverse Events: Thrombocytopenia ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).

2 findings from 1 review

Bortezomib vs no bortezomib

Diarrhoea · All patients with a diagnosis of multiple myeloma

Bortezomib probably leads to higher adverse Events: Diarrhoea ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (moderate certainty).

2 findings from 1 review

Bortezomib vs no bortezomib

Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma

Bortezomib may leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (low certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma

Bortezomib leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (high certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Overall Survival ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma

Bortezomib probably leads to lower overall Survival ‐ Bortezomib versus no bortezomib (same background… compared with no bortezomib (moderate certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma

Bortezomib showed no clear difference in adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma

Bortezomib may leads to higher adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (low certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Adverse effects (cardiac) · All patients with a diagnosis of multiple myeloma

Bortezomib showed no clear difference in adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib… compared with no bortezomib (moderate certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma

Bortezomib leads to higher adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Overall Survival ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma

Bortezomib leads to lower overall Survival ‐ Bortezomib versus no bortezomib (different… compared with no bortezomib (high certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Progression‐free survival (PSF) · All patients with a diagnosis of multiple myeloma

Bortezomib probably leads to lower progression‐Free Survival ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (moderate certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Progression‐free survival · All patients with a diagnosis of multiple myeloma

Bortezomib may leads to lower progression‐Free Survival ‐ Bortezomib versus no bortezomib… compared with no bortezomib (low certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Treatment‐related death ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma

Bortezomib showed no clear difference in treatment‐related death ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (low certainty).

1 finding from 1 review

Bortezomib vs no bortezomib

Treatment‐related death ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma

It is very uncertain whether bortezomib changes treatment‐related death ‐ Bortezomib versus no bortezomib (different… compared with no bortezomib (very low certainty).

1 finding from 1 review